Long Islanders suffering from sleep apnea inundated the sleep center at St. Charles Hospital in Port Jefferson with phone ...

Key Takeaways Patients and doctors are disagreeing about sleep apnea treatment Doctors favor the use of CPAP machines But patients with obesity would rather use Zepbound to ease their apnea MONDAY ...

In today’s Health Alert, obstructive sleep apnea may soon be treated with a simple, once-a-day pill. This first-in-class oral ...

The first oral pill for obstructive sleep apnea could be around the corner after company Apnimed reported positive results ...

Apnimed has scored another phase 3 knockout. The Massachusetts biotech’s daily pill for obstructive sleep apnea reduced the ...

Of the four major GLP-1 drugs on the market, only Zepbound and Mounjaro (known generically as tirzepatide) are FDA-approved to treat sleep apnea in those with a body mass index (BMI) of 30 or higher.

In December, GLP-1 agonist tirzepatide (Zepbound) became the first drug approved to treat moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity after two trials showed it reduced ...

Apnimed's experimental drug reduced breathing interruptions by nearly 46.8% in clinical trials, offering a potential ...

FDA approves Eli Lilly's weight loss drug Zepbound for sleep apnea, expanding use in U.S. The agency's decision expands the use of Zepbound and could potentially pave the way for Eli Lilly to gain ...

But Zepbound is only for people with obesity and sleep apnea, the AASM noted. Also, Zepbound can reduce the severity of sleep apnea through weight loss but might not cure the problem.